Targeting Brain Calcifications to Transform Rare Brain Disorders
ZY-001 (Kamini®) is the first CNS-targeted, disease-modifying therapy for Sturge-Weber Syndrome, Tuberous Sclerosis and other
What We Do
Commitment to Innovation
Commitment to Innovation
Commitment to Innovation
Zy Therapeutics
is a drug development company that utilizes proven pharmacotherapeutics and novel delivery technologies to treat rare and unmet medical needs
Drug Development
Commitment to Innovation
Commitment to Innovation
Zy Therapeutics is a Drug Development Company that specializes in developing pharmaceuticals and other treatments for Rare and Orphan Diseases
Patient Centered
Commitment to Innovation
Patient Centered
Zy Therapeutics represents a revolutionary step forward in the creation of lean biopharmaceuticals that develop life-saving medications in shorter amounts of time and at a fraction of traditional costs
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.